Share
Marino said that Russian Direct Investment Fund (RDIF), which markets the Sputnik V vaccine abroad, also attempted to cancel in-person inspections and did not grant Anvisa technicians permission to access the Gamaleya Institute of Epidemiology and Microbiology in Moscow.
Anvisa s inspectors also were unable to confirm the raw materials that produced the vaccine shot.
The RDIF rejected Anvisa s comments, saying the shot s safety and efficacy had been assessed by regulators in 61 countries which approved it for use. Anvisa s decision to delay the registration of Sputnik V may have been politically motivated, RDIF said in a statement. RDIF regrets the numerous attempts by some countries to oppose the Russian vaccine. including through pressure on foreign regulators.
To improve the performance of our website, show the most relevant news products and targeted advertising, we collect technical impersonal information about you, including through the tools of our partners. You can find a detailed description of how we use your data in our Privacy Policy. For a detailed description of the technologies, please see the Cookie and Automatic Logging Policy.
By clicking on the Accept & Close button, you provide your explicit consent to the processing of your data to achieve the above goal.
You can withdraw your consent using the method specified in the Privacy Policy.
Accept & Close
Sputnik International
Nur 1 Mal impfen - Russland testet Sputnik Light, Export geplant euronews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from euronews.com Daily Mail and Mail on Sunday newspapers.
Al Ain: The United Arab Emirates University (UAEU) is supporting the clinical trial of the novel COVID-19 vaccine developed by the Gamaleya Institute of Epidemiology and Microbiology in Russia.
The vaccine is the world s first registered vaccine based on a well-studied human adenoviral vector-based platform. Sputnik V is nearing the end of the clinical testing process with 40,000 volunteers currently involved in a phase III trial in Russia. Interim results have shown the vaccine has 92 per cent efficacy after the second dose.
Phase III trials have been announced in selected partner countries including the UAE, which has already recruited more than 500 volunteers.
Russian Sputnik vaccine in UAE: Trial partnership announced
WAM/Abu Dhabi
Reuters
UAEU to be first university in the MENA region to study the vaccine and expected to publish the results of the trial.
The UAE University (UAEU) is supporting the clinical trial of the novel Covid-19 vaccine developed by the Gamaleya Institute of Epidemiology and Microbiology in Russia called Sputnik V. This is the first university in the MENA region to study the vaccine and is expected to publish the results of the trial in international peer-reviewed journals.
Phase III trials have already been announced in selected partner countries including the UAE, which has already recruited more than 500 volunteers.